| D007223 |
Infant |
A child between 1 and 23 months of age. |
Infants |
|
| D007231 |
Infant, Newborn |
An infant during the first 28 days after birth. |
Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants |
|
| D012141 |
Respiratory Tract Infections |
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. |
Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection |
|
| D006760 |
Hospitalization |
The confinement of a patient in a hospital. |
Hospitalizations |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000069455 |
Palivizumab |
A humanized monoclonal antibody and ANTIVIRAL AGENT that is used to prevent RESPIRATORY SYNCYTIAL VIRUS INFECTIONS in high risk pediatric patients. |
MEDI 493,MEDI-493,Monoclonal Antibody MEDI-493,Synagis,MEDI493,Monoclonal Antibody MEDI 493,Monoclonal Antibody MEDI493 |
|
| D000911 |
Antibodies, Monoclonal |
Antibodies produced by a single clone of cells. |
Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal |
|
| D000998 |
Antiviral Agents |
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. |
Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral |
|
| D061067 |
Antibodies, Monoclonal, Humanized |
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. |
Antibodies, Humanized,Humanized Antibodies |
|
| D018357 |
Respiratory Syncytial Virus Infections |
Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported. |
RSV Infection,Infections, Respiratory Syncytial Virus,Respiratory Syncytial Virus Infection,Infection, RSV,RSV Infections |
|